A Multiaxial Systematic Review On Contemporary Oncotherapeutic Armamentarium And Lobectomy‑Centric Surgical Stratagems In Lung Carcinomas: Histopathological‑Radiological Correlatives, Molecularly Targeted Regimens, And Immunomodulatory Paradigm Shift

Background: Pulmonary carcinomas—preeminently non-small cell lung cancers (NSCLC)—represent a malignancy of formidable heterogeneity, both in genomic architecture and immunopathological comportment. Historically constrained by anatomically deterministic therapeutic modalities, particularly lobectomy as the gold standard of resection, the contemporary management of lung carcinomas has transitioned into a multidimensional discipline informed by radiogenomic phenotyping, immuno-molecular stratification, and histopathological nuance. This systemic review endeavors to deconstruct, synthesize, and reconceptualize current evidence across surgical, pharmacotherapeutic, and diagnostic spectra through an exhaustive exegesis of twelve landmark investigations. Methods: A comprehensive interrogation of the peer-reviewed oncology literature from 2018 to 2024 was undertaken using PubMed, Embase, and Scopus. Inclusion was restricted to high-impact randomized controlled trials, meta-analyses, and prospective cohort studies published in Q1 journals. Emphasis was placed upon studies exploring the oncological equivalency of lobectomy versus sublobar resections, the therapeutic ramifications of immune checkpoint inhibitors and tyrosine kinase inhibitors in adjuvant and neoadjuvant settings, and the predictive interdependence between histomorphology, radiologic architecture (e.g., ground-glass opacification, spiculation indices), and molecular aberrancy. Data synthesis was conducted with rigorous thematic clustering and critical appraisal of methodological robustness. Results: The integrative analysis of the twelve studies unveiled multiple transformative insights: (1) Lobectomy, while remaining a mainstay, may be oncologically equivalent to segmentectomy in radiologically indolent, lepidic-predominant lesions—particularly when the margin-to-tumor ratio exceeds unity; (2) The deployment of immune checkpoint blockade (e.g., PD-1/PD-L1 inhibitors) post-resection significantly enhances disease-free survival in PD-L1 enriched microenvironments; (3) EGFR-mutated tumors exhibit paradoxical resistance to immunotherapy but respond exquisitely to third-generation TKIs, mandating precise mutational delineation pre-treatment; (4) Radiogenomic and artificial intelligence-based models offer nascent, yet promising, avenues for non-invasive molecular prognostication, albeit constrained by standardization lacunae. Conclusions:The therapeutic matrix of pulmonary carcinoma has irrevocably shifted from monolithic anatomical dogma to a baroque tapestry of interwoven molecular, immunological, and radiological imperatives. Lobectomy, while historically unassailable, now exists within a continuum of biologically modulated resective strategies. Parallelly, oncotherapeutics have transcended cytotoxicity, morphing into immunologically intelligent and genetically precise interventions. However, critical gaps persist—chiefly in the integration of radiogenomic algorithms into clinical pathways, the optimization of perioperative immunotherapy protocols, and the biological staging beyond conventional TNM taxonomy. Future paradigms must, therefore, be epistemologically pluralistic, algorithmically enhanced, and relentlessly individualized.